BlackRock
EIDX

BlackRock’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

BlackRock’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,557,225
Closed -$205M – 5429
2020
Q4 		$205M Buy
1,557,225
+47,477
+3% +$4.2M 0.01% 1597
2020
Q3 		$76.3M Buy
1,509,748
+36,233
+2% +$1.63M ﹤0.01% 2055
2020
Q2 		$70.2M Buy
1,473,515
+56,094
+4% +$2.61M ﹤0.01% 2063
2020
Q1 		$69.4M Buy
1,417,421
+93,732
+7% +$4.78M ﹤0.01% 1869
2019
Q4 		$76M Sell
1,323,689
-11,838
-0.9% -$586K ﹤0.01% 2112
2019
Q3 		$48M Sell
1,335,527
-33,829
-2% -$1.32M ﹤0.01% 2310
2019
Q2 		$42.6M Sell
1,369,356
-244,395
-15% -$6.63M ﹤0.01% 2414
2019
Q1 		$37.8M Buy
1,613,751
+464,387
+40% +$7.45M ﹤0.01% 2416
2018
Q4 		$15.8M Buy
1,149,364
+421,666
+58% +$5.32M ﹤0.01% 2850
2018
Q3 		$7.26M Buy
727,698
+577,698
+385% +$9.5M ﹤0.01% 3373
2018
Q2 		$3.05M Buy
+150,000
New +$3.14M ﹤0.01% 3613

BlackRock's EIDX Position: Q1 2021 in Review

BlackRock sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 1,557,225 shares — an estimated $205M sold.

BlackRock first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $205M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • BlackRock reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • BlackRock sold 1,557,225 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $205M.
  • BlackRock first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • BlackRock's Eidos Therapeutics, Inc. Common Stock position peaked at $205M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.